News

FDA Approves First Drug for Treating Fibromyalgia The U.S. Food and Drug Administration today approved Lyrica (pregabalin), the first drug to treat fibromyalgia, a disorder characterized by pain, fatigue and sleep problems. Lyrica reduces pain and improves daily functions for some patients with fibromyalgia. "Today's new approval marks an important advance, and provides a reason for optimism for the many patients who will receive pain relief with Lyrica," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "However, consumers should understand that some patients did not experience benefit in clinical trials. We still have more progress to make for treatment of this disorder."

WHO Framework Convention on Tobacco Control - second session of Conference of the PartiesThe second session of the Conference of the Parties to the WHO Framework Convention on Tobacco Control (WHO FCTC) will take place from 30 June to 6 July 2007 in Bangkok, Thailand. The Conference of the Parties will discuss matters identified in the first such Conference, which took place in Geneva in February 2006. The work done in between the two sessions will be the starting point for the discussions.

FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension type of pharmacologic agent you are working with,CoSci Med-Tech has the capability to support you from development,registration to marketing.We have collaborated with several primary pharmaceutical enterprises in China and foreign. The U.S. Food and Drug Administration (FDA) today approved Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension, a rare, life-threatening condition characterized by continuous high blood pressure within the arteries of the lungs. "Letairis represents a valuable addition to the treatment alternatives for this orphan disease," said John Jenkins, M.D., director of FDA's Office of New Drugs. "Letairis is similar to an existing drug, but offers the potential for fewer drug interactions." In pulmonary arterial hypertension, the small arteries in the lungs become narrowed or blocked, and the heart must work harder to pump the blood through them. Over time, the overworked heart muscle may become weak and lose its ability to pump enough blood through the lungs. Symptoms include shortness of breath, fatigue, chest pain, dizzy spells and fainting. About 100,000 people in the United States have pulmonary arterial hypertension.